Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib versus placebo plus lanreotide in progressive advanced/metastatic midgut carcinoid tumors
2012-001098-94Phase 2Completed
- Sponsor
- GERCOR
- Start
- Aug 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in midgut neuroendocrine tumor (MNET) and Carcinoid Tumor (CT) comparing Sunitinib plus lanreotide with Placebo plus lanreotide (2 arms). Primary endpoint: Progression-Free Survival. Started Aug 2012; status: completed.
02
Drugs
sunitiniblanreotide
03
Conditions
midgut neuroendocrine tumor (MNET)Carcinoid Tumor (CT)
Beyond the preview
Go deeper on 2012-001098-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001098-94.